Status: Recruiting
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
J8G-MC-JDIA (AJX-101) is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II Janus Kinase 2 (JAK2) inhibitor, LY5830966, in participants with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.
Participants needed: 256
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyUpdated: Oct 9, 2026Locations: 21
Eligibility criteria
Diagnosis of PMF, post-PV MF, or post-ET MF. [+14]
Prior splenectomy or splenic irradiation within 3 months. [+16]